The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
The Cost-Effectiveness of Preexposure Prophylaxis for HIV Prevention in the United States in Men Who Have Sex With Men
Open accessAbstract
BACKGROUND: A recent randomized, controlled trial showed that daily oral preexposure chemoprophylaxis (PrEP) was effective for HIV prevention in men who have sex with men (MSM). The Centers for Disease Control and Prevention recently provided interim guidance for PrEP in MSM at high risk for HIV. Previous studies did not reach a consistent estimate of its cost-effectiveness. OBJECTIVE: To estimate the effectiveness and cost-effectiveness of PrEP in MSM in the United States. DESIGN: Dynamic model of HIV transmission and progression combined with a detailed economic analysis. DATA SOURCES: Published literature. TARGET POPULATION: MSM aged 13 to 64 years in the United States. TIME HORIZON: Lifetime. PERSPECTIVE: Societal. INTERVENTION: PrEP was evaluated in both the general MSM population and in high-risk MSM and was assumed to reduce infection risk by 44% on the basis of clinical trial results. OUTCOME MEASURES: New HIV infections, discounted quality-adjusted life-years (QALYs) and costs, and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: Initiating PrEP in 20% of MSM in the United States would reduce new HIV infections by an estimated 13% and result in a gain of 550,166 QALYs over 20 years at a cost of $172,091 per QALY gained. Initiating PrEP in a larger proportion of MSM would prevent more infections but at an increasing cost per QALY gained (up to $216,480 if all MSM receive PrEP). Preexposure chemoprophylaxis in only high-risk MSM can improve cost-effectiveness. For MSM with an average of 5 partners per year, PrEP costs approximately $50,000 per QALY gained. Providing PrEP to all high-risk MSM for 20 years would cost $75 billion more in health care-related costs than the status quo and $600,000 per HIV infection prevented, compared with incremental costs of $95 billion and $2 million per infection prevented for 20% coverage of all MSM. RESULTS OF SENSITIVITY ANALYSIS: PrEP in the general MSM population would cost less than $100,000 per QALY gained if the daily cost of antiretroviral drugs for PrEP was less than $15 or if PrEP efficacy was greater than 75%. LIMITATION: When examining PrEP in high-risk MSM, the investigators did not model a mix of low- and high-risk MSM because of lack of data on mixing patterns. CONCLUSION: PrEP in the general MSM population could prevent a substantial number of HIV infections, but it is expensive. Use in high-risk MSM compares favorably with other interventions that are considered cost-effective but could result in annual PrEP expenditures of more than $4 billion. PRIMARY FUNDING SOURCE: National Institute on Drug Abuse, Department of Veterans Affairs, and National Institute of Allergy and Infectious Diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Prevention of HIV-1 infection with early antiretroviral therapy.
Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., Hakim, J. G., Kumwenda, J., Grinsztejn, B., Pilotto, J. H. S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105243 · Cited by 6,873
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096
Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda.
Wawer, M. J., Gray, R. H., Sewankambo, N. K., Serwadda, D., Li, X., Laeyendecker, O., Kiwanuka, N., Kigozi, G., Kiddugavu, M., Lutalo, T., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/429411 · Cited by 1,258
Estimated HIV Incidence in the United States, 2006–2009
Prejean, J., Song, R., Hernandez, A., Ziebell, R., Green, T., Walker, F., Lin, L. S., An, Q., Mermin, J., Lansky, A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017502 · Cited by 1,071
Kamb, M. L., Fishbein, M., Douglas, Jr., Rhodes, F., Rogers, J., Bolan, G., Zenilman, J., Hoxworth, T., Malotte, C. K., Iatesta, M., et al. (1998) · JAMA · doi:10.1001/jama.280.13.1161 · Cited by 973
Clinical and epidemiologic features of primary HIV infection.
Schacker, T., Collier, A. C., Hughes, J., Shea, T., & Corey, L. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-4-199608150-00001 · Cited by 703
Koblin, B. A., Chesney, M. A., Husnik, M. J., Bozeman, S., Celum, C. L., Buchbinder, S., Mayer, K., McKirnan, D., Judson, F. N., Huang, Y., et al. (2003) · American Journal of Public Health · doi:10.2105/ajph.93.6.926 · Cited by 325
Comparing the costs of HIV screening strategies and technologies in health-care settings
Farnham, P. G., Hutchinson, A. B., Sansom, S. L., & Branson, B. M. (2008) · Public Health Reports® · doi:10.1177/00333549081230s307 · Cited by 69
Research works printed but not linked: 69
- Centers for Disease Control and Prevention (CDC), 2011, MMWR Morb Mortal Wkly Rep, 60, 65
- 10.1086/597095 · DOI · Paper page
- 10.1097/QAD.0b013e32830e00f5 · DOI · Paper page
- 10.1097/QAD.0b013e328349f067 · DOI
- Centers for Disease Control and Prevention (CDC), 2008, MMWR Morb. Mortal Wkly Rep, 57, 1073
- 10.1097/OLQ.0b013e3181ce122b · DOI
- Arias E, 2007, Natl Vital Stat Rep, 56, 1
- 10.1086/386333 · DOI · Paper page
- 10.1016/S0891-5520(05)70135-5 · DOI
- 10.1086/590501 · DOI · Paper page
- 10.1097/QAD.0b013e32826fb6a6 · DOI
- 10.1097/00002030-200406180-00010 · doi:10.1097/00002030-200406180-00010
- 10.1016/j.vaccine.2009.06.063 · DOI
- 10.7326/0003-4819-126-12-199706150-00003 · DOI · Paper page
- 10.1086/524686 · DOI
- 10.7326/0003-4819-153-12-201012210-00004 · DOI · Paper page
- 10.1097/QAD.0b013e328133f285 · DOI · Paper page
- 10.1097/00002030-200305020-00012 · DOI
- 10.1086/512816 · DOI
- 10.1097/00002030-200207260-00010 · DOI · Paper page
- 10.7326/0003-4819-145-6-200609190-00005 · DOI · Paper page
- 10.1097/00126334-200404150-00011 · DOI · Paper page
- 10.1097/01.aids.0000238410.67700.d1 · DOI
- 10.1097/00007435-199808000-00006 · DOI
- 10.1056/NEJMsa042657 · DOI · Paper page
- 10.1016/S0140-6736(08)61115-0 · DOI · Paper page
- 10.1056/NEJM200003303421303 · DOI · Paper page
- 10.1126/science.280.5371.1889 · DOI · Paper page
- 10.1097/01.qai.0000194234.31078.bf · DOI
- 10.7326/0003-4819-146-8-200704170-00010 · DOI · Paper page
- Sanchez T, 2006, MMWR Surveill Summ, 55, 1
- 10.1007/s11524-006-9135-5 · DOI
- 10.1097/QAI.0b013e3181ee4c62 · DOI
- 10.1007/s10461-009-9582-6 · DOI
- 10.1097/01.qai.0000151079.33935.79 · DOI · Paper page
- 10.7326/0003-4819-134-1-200101020-00010 · DOI · Paper page
- 10.1056/NEJM200103153441107 · DOI · Paper page
- 10.1097/01.mlr.0000228021.89490.2a · DOI · Paper page
- 10.1097/00002030-199905280-00013 · DOI
- 10.1097/01.qai.0000243090.32866.4e · DOI
- 10.1377/hlthaff.23.4.176 · DOI · Paper page
- 10.7326/0003-4819-145-11-200612050-00004 · DOI · Paper page
- Branson BM, 2006, MMWR Recomm Rep, 55, 1
- 10.1001/jama.300.5.555 · DOI · Paper page
- 10.1089/apc.2010.0222 · DOI
- 10.1007/s11904-010-0057-1 · DOI
- 10.1097/QAI.0b013e3181e19a54 · DOI · Paper page
- 10.1089/apc.2010.0173 · doi:10.1089/apc.2010.0173
- 10.1097/QAI.0b013e31818d5a27 · DOI · Paper page
- 10.1097/QAI.0b013e31815e4041 · DOI · Paper page
- 10.1007/s11136-005-8485-x · doi:10.1007/s11136-005-8485-x
- 10.7326/0003-4819-154-3-201102010-00007 · DOI · Paper page
- 10.1371/journal.pmed.1000423 · DOI
- 10.1097/00002030-199510000-00001 · DOI
- 10.1177/0272989X9301300202 · DOI · Paper page
- 10.1001/jama.1997.03550230061038 · DOI
- 10.7326/0000605-200912150-00157 · DOI
- 10.1016/j.vaccine.2004.12.033 · DOI
- 10.1046/j.1524-4733.2003.00213.x · DOI
- 10.7326/0003-4819-139-2-200307150-00011 · DOI
- 10.1097/00042560-199709010-00009 · DOI · Paper page
- 10.1177/0272989X02238300 · DOI · Paper page
- 10.1097/MLR.0b013e31803dce05 · DOI
- 10.1177/0272989X06290495 · DOI · Paper page
- 10.1097/QAD.0b013e328010c7d0 · DOI
- 10.1001/archinte.1996.00440040066007 · DOI
- 10.1016/S0002-9343(00)00583-0 · doi:10.1016/s0002-9343(00)00583-0
- 10.1007/s11908-006-0008-6 · DOI · Paper page
- 10.1056/NEJMsa042088 · DOI · Paper page
Cited by
Liu, A. Y., Cohen, S. E., Vittinghoff, E., Anderson, P. L., Doblecki-Lewis, S., Bacon, O., Chege, W., Postle, B. S., Matheson, T., Amico, K. R., et al. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.4683 · Cited by 602
Smith, D. K., Van Handel, M., Wolitski, R. J., Stryker, J. E., Hall, H. I., Prejean, J., Koenig, L. J., & Valleroy, L. A. (2015) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6446a4 · Cited by 352
Pathela, P., Braunstein, S. L., Blank, S., & Schillinger, J. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit437 · Cited by 146
Uyei, J., Fiellin, D. A., Buchelli, M., Rodriguez-Santana, R., & Braithwaite, R. S. (2017) · The Lancet Public Health · doi:10.1016/s2468-2667(17)30006-3 · Cited by 55
On behalf of the PROUD Study Group, Dolling, D. I., Desai, M., McOwan, A., Gilson, R., Clarke, A., Fisher, M., Schembri, G., Sullivan, A. K., Mackie, N., et al. (2016) · Trials · doi:10.1186/s13063-016-1286-4 · Cited by 51
Metadata
- Authors
- Juusola, J. L., Brandeau, M. L., Owens, D. K., & Bendavid, E.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2012-04-17
- Volume
- 156
- Issue
- 8
- Pages
- 541-550
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W1981177608
- Cited by
- 235
- References
- 11
- FWCI
- 15.18
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Cost-Effectiveness of Preexposure Prophylaxis for HIV Prevention in the United States in Men Who Have Sex With Men. https://app.cochat.ai/papers/10.7326/0003-4819-156-8-201204170-00001
- The paper
- Juusola, J. L., Brandeau, M. L., Owens, D. K., & Bendavid, E. (2012). The Cost-Effectiveness of Preexposure Prophylaxis for HIV Prevention in the United States in Men Who Have Sex With Men. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-156-8-201204170-00001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.